Evrysdi is the brand name for Risdiplam, a drug that was approved by the Food and Drug Administration (FDA) on August 7, 2020. It is used for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Frequently Asked Questions About EvrysdiTM
Is my child eligible for treatment with EvrysdiTM?
Your child must have the survival motor neuron 1 (SMN1) genetic mutation that causes SMA. A genetic confirmation is necessary to confirm your child’s eligibility and must be older than 2 months old.
How does EvrysdiTM work?
EvrysdiTM is designed to work by helping to make and maintain more SMN protein that your child is lacking.
How is EvrysdiTM given to patients?
EvrysdiTM is a liquid that can be given by mouth or through a feeding tube at home, once a day.
What is the benefit of EvrysdiTM?
Clinical trials have shown that patients with Type 1 SMA had an increase in ability to sit unsupported for at least 5 second and were alive and could breathe without permanent support. Motor function improved in children with Type 2 and 3 SMA.
Is EvrysdiTM covered by insurance?
Insurance coverage varies from plan to plan, which we recommend talking with your insurance carrier before starting treatment.
Genentech’s support service, MySMA Support, can help provide additional information about EvrysdiTM. Partnership and Access Liaisons (PALs) are the local contacts for MySMA Support. They work with the rest of the MySMA Support team to help you throughout the treatment journey. A Case Manager will also help navigate coverage and financial support, they partner closely with PALs and healthcare providers to help you understand the health insurance process and identify financial support options.